References
- Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–613
- Rossouw J E, Anderson G L, Prentice R L, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
- Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–427
- Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365: 1543–1551
- EMEA Public Statement on recent publications regarding hormone replacement therapy: The European Agency for the Evaluation of Medicinal Products. 2003, URL: www.emea.europa.eu/pdfs/human/press/pus/3306503en.pdf
- Skouby S O, Al-Azzawi F, Barlow D, et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 2005; 51: 8–14
- Faber A, Bouvy M L, Loskamp L, et al. Dramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up study. Br J Clin Pharmacol 2005; 60: 641–647
- Usher C, Teeling M, Bennett K, Feely J. Effect of clinical trial publicity on HRT prescribing in Ireland. Eur J Clin Pharmacol 2006; 62: 307–310
- Hersh A L, Stefanick M L, Stafford R S. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004; 291: 47–53
- Ramos E, Lopes C, Barros H. Investigating the effect of nonparticipation using a population-based case-control study on myocardial infarction. Ann Epidemiol 2004; 14: 437–441
- Santos A C, Barros H. Smoking patterns in a community sample of Portuguese adults, 1999–2000. Prev Med 2004; 38: 114–119
- Rocha O, Lunet N, Costa L, Barros H. [Osteoporosis treatment in Portugal: trends and geographical variation]. Acta Med Port 2006; 19: 373–380
- Ettinger B, Grady D, Tosteson A N, Pressman A, Macer J L. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003; 102: 1225–1232
- Taylor A W, MacLennan A H, Avery J C. Postmenopausal hormone therapy: who now takes it and do they differ from non-users?. Aust N Z J Obstet Gynaecol 2006; 46: 128–135
- Instituto Nacional da Farmácia e do Medicamento. Terapêutica Hormonal de Substituição (THS) – Women's Health Initiative (WHI). INFARMED. 2002, URL: http://www.infarmed.pt/portal/page/portal/INFARMED/MAIS_ALERTAS/ALERTAS_DE_SEGURANCA/Terap%EAutica%20Hormonal%20de%20Substitui%E7%E3o%20(THS)%20-%20Women%92s%20Health
- Instituto Nacional da Farmácia e do Medicamento. Actualização da informação relativa à Terapêutica Hormonal de Substituição, resultantes do estudo Million Women. INFARMED. 2003, URL: http://www.infarmed.pt/portal/pls/portal/docs/1/21373.PDF
- Instituto Nacional da Farmácia e do Medicamento. Informação de segurança adicional sobre terapêutica hormonal de substituição (THS) – THS deixa de ser recomendada como tratamento de primeira escolha na Prevenção de Osteoporose. INFARMED. 2003, URL: http://www.infarmed.pt/portal/page/portal/INFARMED/MAIS_NOVIDA DES/ANOS_ANTERIORES/NOVIDADES_2003/ nt_03_12_2003.doc
- Instituto Nacional da Farmácia e do Medicamento. Uso da Terapêutica Hormonal de Substituição (THS) para Prevenção de Osteoporose: Informação Importante para Mulheres Utilizadoras da THS. INFARMED. 2003, URL: http://www.infarmed.pt/portal/page/portal/INFA RMED/MAIS_ALERTAS/ALERTAS_DE_SEGU RANCA/0D7A159A49BB9057E04010AC31204 B86
- Jornal Público. Edição Impressa. PUBLICO.PT. URL: http://jornal.publico.clix.pt/default.asp? url=search%2Easp%3Fweb%3DUH%26q%3Dterapeutica%2520hormonal%2520substituicao %26check%3D1
- Marantes I, Barros H. Osteoporose: o que sabem e o que pensam as mulheres portuguesas?. Arq Med 2004; 18: 78–82